Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 13.04.2026 FEXD.LN IE00BWTNMB87 458,343.00 USD 43,015,411.23 93.850  ...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 2,174,000.00 MATURING: 20-Jan-2061 ISIN: XS2601814754 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Mar-2026 TO 20-Apr-2026 HAS BEEN FIXED AT 13.46 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Apr-2026 WILL AMOUNT TO: GBP 26,175.70 PER GBP 2,289,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 13.04.2026 FEX.LN IE00B8X9NW27 1,082,269.00 USD 114,496,738.46 105.793  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest S&P 500 Dividend Aristocrats Target Income UCITS ETF 13.04.2026 KNG.LN IE000SNMGYT5 850,002.00 USD 17,339,882.33 20.400  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 13.04.2026 GFEB.LN IE000X8M8M80 700,002.00 USD 26,420,137.16 37.743  ...

EPALINGES, Switzerland--(BUSINESS WIRE)--Novigenix AI, a leader in AI-driven healthcare solutions, today announced the presentation of new data at the American Association for Cancer Research (AACR) 2026 Annual Meeting demonstrating, for the first time in a human clinical setting, the dynamic role of the immune system in response to radioligand therapy in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET).1 The study, conducted in collaboration with RadioMedix, Inc....